Ann: CardioCel gains special access in Singapore, page-34

You guys have misread the significance of this singapore announcement.

4 specialist surgeons pre-approved in 4 different centres in singapore, ie the best hospitals with the worlds best cardiologists in each one, its like granting one knighthood to each shire, the shire populace will be bound by that area for that one surgeon for that one product, this approval is broader than that in Australia and is a further global recognition of cardiocel, they will trial it on patients 2-3 operations daily and then wont go back, before you know it 10 operations daily at 20 singapore centres and then the large singapore orders come in..same pattern as in europe and US...

Theres no going back after this is used by the best surgeons, just like the digital mouse or smartphone.. for biotech its just like viagra and penicilin, . The appetite just gets larger.

I am calling an exceeding of Baillieu Holsts income projection for 2015 FYR by 20-30% of $14M, to around $16M+ with by Jan 60+ centres and growing exponentially /.... maybe 100-120 centres by 30 Jun 2015.

By 30 June 2015, $14M ahz INCOME may look way too low. Once the uptake floods to the global centres, theres no stopping it and it will grow and grow exponentially to the smaller and smaller centres... thats biotech hence why the OZ market just does not get AHZ or biotech.. its all about the approvals as the patients and doctors want it and after the approvals its an exponential flood......foolish and naive to sell at these low SPs